Bringing It Together: Personalized Treatment of CKM Syndrome

This closing video brings the CKM care pathway full circle by presenting a four-step framework: screen, assess, stage, and treat. PA Le discusses how to personalize care plans and prioritize therapies with strong evidence for reducing cardiovascular events, kidney decline, and mortality. He also addresses shared decision-making strategies and practical ways to overcome common barriers such as time constraints and low health literacy. The series concludes with an empowering message for PAs to lead CKM care confidently and collaboratively.

Key Takeaways:

Early detection of CV, kidney, and metabolic conditions that have the potential to compound and increase the risk of ASCVD and HF is critical.
Many therapies have evidence for treating more than one CKM-related disease.
Provide patient education and use shared decision-making regarding treatment.

Previous Video Next Series

Speaker

Click on the photo below to learn more about the speaker.

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

References and Additional Resources:

Deniz S, Akbolat M, Çimen M, Ünal Ö. The mediating role of shared decision-making in the effect of the patient-physician relationship on compliance with treatment. J Patient Exp. 2021;8:23743735211018066. doi:10.1177/23743735211018066

Hoque F. Shared Decision-Making in patient care: Advantages, barriers and potential solutions. J Brown Hosp Med. 2024;3(4):13-15. doi:10.56305/001c.122787

Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation. 2023;148(24):1982-2004. doi:10.1161/CIR.0000000000001191

Montori VM, Ruissen MM, Hargraves IG, Brito JP, Kunneman M. Shared decision-making as a method of care. BMJ Evid Based Med. 2023;28(4):213-217. doi:10.1136/bmjebm-2022-112068

Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450-462. doi:10.1161/CIRCULATIONAHA.123.067584

Supported by

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

Viet is an Associate Professor of Research and Preventive Cardiology PA at Intermountain Medical Center and co-directs the Preventive Cardiology Clinic. He has a bachelor’s in exercise science/athletic training, trained as a physician assistant at the University of Utah School of Medicine, and obtained his doctorate in Health Professions Education. He is Principal/Sub-Investigator on clinical trials and has authored/co-authored over 80 abstracts and 50 publications. He is past president of the Academy of PAs in Cardiology, past co-chair of the American College of Cardiology PA Work Group, and serves as the President of the Utah Academy of PAs.